The Department of Biotechnology (DBT), Ministry of Science & Technology, Government of India and the International AIDS Vaccine Initiative signed an agreement today to address a major obstacle in AIDS vaccine development: the design of candidate vaccines to elicit neutralizing antibodies against HIV. A new Indian Medicinal Chemistry Programme, co-sponsored and co-funded by IAVI and the Department of Biotechnology, will comprise top Indian and U.S. scientists tasked with accelerating the pace of AIDS vaccine discovery and developing creative concepts for the next generation of AIDS vaccines.
Union Minister for Science and Technology and Earth Sciences Shri. Kapil Sibal said that vaccine research is so critical that the Health Ministry and the Science and Technology Ministry have joined hands to provide the effort the support it needs.
Indias Department of Biotechnology is delighted to be a part of the global search for an efficacious AIDS vaccine. This was stated by Dr. Maharaj K. Bhan, Secretary, DBT. He said only through these kinds of biotechnology ventures involving international collaborations and the sharing of scientific knowledge, can we hope to solve the complex biomedical problems of our times.
According to Seth Berkley, CEO and President of IAVI, this new partnership will broaden ongoing efforts in India to find an AIDS vaccine.
The Indian Programme will complement the work of IAVIs Neutralizing Antibody Consortium (NAC), a team of internationally recognized scientists working on the neutralizing antibody challenge. Researchers believe an ideal AIDS vaccine must evoke an antibody response that can block HIV from entering healthy cells, as well as reduce the amount of viral dissemination through a cell-mediated immune response to HIV-infected cells. Yet today, virtually all current vaccine candidates in the pipeline are based on cell-mediated immune responses alone, failing to target the second cr
itical arm of the human immune system.
The first component of the DBT-IAVI Programme will consist of a collaboration of principal investigators from different academic research laboratories to design novel HIV antigens. The investigators include Professor Virander S. Chauhan of the International Centre for Genetic Engineering and Biotechnology, New Delhi; Professor Raghavan Varadarajan of the Indian Institute of Science, Bangalore; Dr. Stephen Kaminsky of IAVIs AIDS Vaccine Development Laboratory, New York; and Dr. Philip Dawson of The Scripps Research Institute, California. IAVI and DBT may select additional principal investigators, contract researchers, or partners in India to participate in the Programme, and will discuss ways to build infrastructure for subsequent HIV/AIDS vaccine candidate evaluation.
At a later stage, based on their initial research and vaccine design concepts, both partners expect to work with an Indian manufacturer to assist with high throughput synthesis, antigen chemical characterization and potency evaluation of proposed AIDS vaccine candidates.
The Department of Biotechnology (DBT) was established under the Indian Ministry of Science and Technology in 1986 to give impetus to the development of the field of modern biology and biotechnology in India. Significant achievements include the growth and application of biotechnology in the broad areas of medical biotechnology and health care, agriculture, animal sciences, environment, and industry. DBT has more than 5000 research publications, 4000 post-doctoral students, several technologies transferred to industries and patents (including US patents) to its credit. Initiatives have been taken to promote transgenic research in plants with emphasis on pest and disease resistance, nutritional quality, silk-worm genome analysis, molecular biology of human genetic disorders, brain research, plant genome research, development, validation and commercialisat
ion of diagnostic kits and vaccines for communicable diseases, food biotechnology, biodiversity conservation and bioprospecting, setting up of micropropagation parks and biotechnology based development for SC/ST, rural areas, women and for different States. Necessary guidelines for transgenic plants, recombinant vaccines and drugs have also been evolved. A strong base of indigenous capabilities has been created. For further information, refer www.dbtindia.gov.in.
The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. Founded in 1996 and operational in 24 countries, IAVI and its network of collaborators research and develop vaccine candidates. IAVI's financial and in-kind supporters include the Alfred P. Sloan Foundation, the Bill & Melinda Gates Foundation, The John D. Evans Foundation, The New York Community Trust, the James B. Pendleton Charitable Trust, The Rockefeller Foundation, The Starr Foundation, The William and Flora Hewlett Foundation; the Governments of Canada, Denmark, Ireland, The Netherlands, Norway, Sweden, the United Kingdom, and the United States, the Basque Autonomous Government as well as the European Union; multilateral organizations such as The World Bank; corporate donors including BD (Becton, Dickinson & Co.), Continental Airlines, Google Inc., Merck & Co., Inc. and Pfizer Inc; leading AIDS charities such as Broadway Cares/Equity Fights AIDS and Until There's A Cure Foundation; other private donors such as The Haas Trusts; and many generous individuals from around the world.
Related medicine news :1
. Never Forget Brushing And Flossing2
. Forgetful? You May Be Losing More Than Just Your Memory3
. When Your Pet Forgets Who You Are4
. Forge Ahead On Folate Fortification5
. Chemo Brain- Nothing Forgettable About It6
. DBT And IAVI Forge Partnership To Develop “Next Generation” Vaccine Candidats7
. Forgetfulness Actually Helps Your Brain Stay Healthy8
. British Healthcare Mission Explores Partnership Possibilities With Indian Healthcare Sector9
. Partnership Between Diabetes India And Elsevier Announced10
. Betterment Of Health In Case Of Gay And Lesbian Civil Partnerships11
. Private Public Partnership To Tackle TB, In Karnataka